Evidence map›Paper›PMID 39107832›Full record

ArticleAIDS research and therapy2024

Willingness to trade-off years of life for an HIV cure - an experimental exploration of affective forecasting.

Ilona Fridman, Nir Eyal, Karen A Scherr, Judith S Currier, Kenneth A Freedberg, Scott D Halpern, Daniel R Kuritzkes, Monica Magalhaes, Kathryn I Pollak, Peter A Ubel

Abstract read
In one paragraph

Article in AIDS research and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ilona FridmanLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Chapel Hill, 450 West Dr, NC, 27599, USA. Ilona_fridman@med.unc.edu.
Nir EyalSchool of Public Health, and Philosophy, Rutgers University Institute for Health, 112 Paterson St, NJ, 08901, USA.
Karen A ScherrDepartment of Family Medicine and Community Health, Duke School of Medicine, 2301 Erwin Rd, Durham, 27710, NC, USA.
Judith S CurrierDepartment of Medicine, University of California Los Angeles, 911 Broxton Ave, Suite 30, Los Angeles, CA, 90095, USA.
Kenneth A FreedbergMedical Practice Evaluation Center, Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, 100 Cambridge St, Suite 1600, Boston, MA, 02115, USA.
Scott D HalpernDepartments of Medicine, Medical Ethics and Health Policy, and Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
Daniel R KuritzkesDivision of Infectious Diseases Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne St, Rm 449, Cambridge, MA, 02139, USA.
Monica MagalhaesRutgers University Institute for Health, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Kathryn I PollakCancer Control and Population Sciences in the Duke Cancer Institute, 2424 Erwin Road, Suite 602, Durham, NC, 27705, USA.
Peter A UbelDepartment of Population Health Science, Fuqua School of Business, School of Medicine, Sanford School of Public Policy, Duke University, 100 Fuqua Drive., Durham, NC, 27708, USA.

Funding

UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
HIV cure studies: risk, risk perception, and ethicsR56AI114617 · NIAID · HARVARD MEDICAL SCHOOL · PI EYAL, NIR · 2014 to 2014
$528k
National Institute of Allergy and Infectious Diseases R01AI042006NIAID NIH HHS R01 AI042006NIAID NIH HHS R56 AI114617NIAID NIH HHS UM1 AI069424
6 · The paper itself

Abstract

backgroundIn the US, 1.2 million people live with HIV (PWH). Despite having near-normal life expectancies due to antiretroviral therapy (ART), many PWH seek an HIV cure, even if it means risking their lives. This willingness to take risks for a cure raises questions about "affective forecasting biases," where people tend to overestimate the positive impact of future events on their well-being. We conducted a study to test two interventions to mitigate affective forecasting in the decisions of PWH about taking HIV cure medication.

methodsWe recruited PWH to complete a 30-minute survey about their current quality of life (QoL) and the QoL they anticipate after being cured of HIV, and assigned them to either no additional intervention, to one of two interventions intended to reduce affective forecasting bias, or to both interventions: (1) a defocusing intervention designed to broaden the number of life domains people consider when imagining life changes associated with new circumstances (e.g. HIV cure); and (2) an adaptation intervention to help them gauge fading of strong emotions over time. The study design included a 2 × 2 design: defocusing (yes/no) x adaptation (yes/no) intervention. We assessed PWH's willingness to take hypothetical HIV sterilizing cure medication using the Time Trade-Off (TTO) and their quality of life predictions with WHOQOL-HIV.

results296 PWH participated. Counter to what we had hypothesized, neither intervention significantly reduced PWH's willingness to trade time for a cure. Instead, the defocusing intervention increased their willingness to trade time (IRR 1.77, p = 0.03). Exploratory analysis revealed that PWH with lower current quality of life who received the defocusing intervention were more willing to trade time for a cure.

conclusionThese negative findings suggest that either these biases are difficult to overcome in the settings of HIV curative medication or other factors beyond affective forecasting biases influence willingness to participate in HIV curative studies, such as respondents' current quality of life.

Indexed as

HIV InfectionsQuality of LifeAdultAnti-HIV AgentsFemaleForecastingHumansLife ExpectancyMaleMiddle AgedSurveys and QuestionnairesAnti-HIV Agents

Identifiers

PMID39107832
PMCPMC11304558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.